Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Current Drug Targets
Title:Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Volume: 16 Issue: 3
Author(s): Mohammad Bashashati, Hamid R. Habibi, Ali Keshavarzian, Max Schmulson and Keith A. Sharkey
Affiliation:
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Export Options
About this article
Cite this article as:
Bashashati Mohammad, Habibi R. Hamid, Keshavarzian Ali, Schmulson Max and A. Sharkey Keith, Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150120104012
DOI https://dx.doi.org/10.2174/1389450116666150120104012 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity
Central Nervous System Agents in Medicinal Chemistry Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development
Current Medicinal Chemistry The Potential Role of Statins in Pneumonia
Current Respiratory Medicine Reviews The Treatment of Chronic Hepatitis C not Responding to Interferon
Current Pharmaceutical Design Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets